Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Colorectal Cancer Specialty Channel

Colorectal Cancer
Specialty Channel
Abigail Zamorano, MD, MPHS, UT Health Houston
Videos
Using the PREMM5 Model for Lynch Syndrome Screening in Colorectal or Endometrial Cancer
10/08/2024
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS,...
10/08/2024
Oncology
FDA Approval
FDA Approves Multitarget Stool DNA Test for Patients at Average Risk for Colorectal Cancer
10/07/2024
Based on results from the BLUE-C study, the FDA has approved the Cologuard Plus™ test for patients 45 years and older at average risk for colorectal cancer.
Based on results from the BLUE-C study, the FDA has approved the Cologuard Plus™ test for patients 45 years and older at average risk for colorectal cancer.
Based on results from the BLUE-C...
10/07/2024
Oncology
News
Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer
10/02/2024
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
Neoadjuvant Nivolumab Plus Ipilimumab Showed Promise Among Patients With Locally Advanced Mismatch-Repair Deficient Colon Cancer
07/18/2024
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.
According to results from the...
07/18/2024
Oncology
News
Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer
07/11/2024
Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...
Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...
Final analysis results from the...
07/11/2024
Oncology
News
FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer
06/21/2024
Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.
Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.
Based on results from the...
06/21/2024
Oncology
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
Conference Coverage
Ipilimumab Biosimilar Added to Sintilimab in Neoadjuvant Setting Improves Response Rates Among Patients With MSI-H/dMMR Colorectal Cancer
05/28/2024
According to results from a phase 1b study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...
According to results from a phase 1b study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...
According to results from a...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer
04/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL...
04/09/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology

Advertisement

News

News
Neoadjuvant Nivolumab Plus Ipilimumab Showed Promise Among Patients With Locally Advanced Mismatch-Repair Deficient Colon Cancer
07/18/2024
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.
According to results from the...
07/18/2024
Oncology
News
Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer
07/11/2024
Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...
Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...
Final analysis results from the...
07/11/2024
Oncology
News
FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer
06/21/2024
Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.
Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.
Based on results from the...
06/21/2024
Oncology
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
Conference Coverage
Ipilimumab Biosimilar Added to Sintilimab in Neoadjuvant Setting Improves Response Rates Among Patients With MSI-H/dMMR Colorectal Cancer
05/28/2024
According to results from a phase 1b study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...
According to results from a phase 1b study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...
According to results from a...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer
04/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL...
04/09/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
Thierry André, MD, Saint Antoine Hospital
Videos
Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer
01/23/2024
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the...
01/23/2024
Oncology
Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology

Interactive Features

Quiz
Quiz: Incidence of Anal Cancer
05/18/2023
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has...
05/18/2023
Oncology
Test Your Knowledge
Quiz: Does Pembrolizumab Plus CRT After FOLFOX Provide Benefit for LARC?
09/03/2021
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the...
09/03/2021
Oncology
Quiz
Quiz: Which Therapy Enhances Tumor Immunologic Response in LARC?
08/09/2021
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer
04/22/2021
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a...
04/22/2021
Oncology
Test Your Knowledge
Quiz: Does Coffee Consumption Yield Benefit in CRC?
04/05/2021
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds...
04/05/2021
Oncology
Test Your Knowledge
Quiz: What Are the 3 Current Modalities for Rectal Cancer?
03/24/2021
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3...
03/24/2021
Oncology
Test Your Knowledge
Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology
Test Your Knowledge
Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?
06/22/2020
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma...
06/22/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Neoadjuvant Nivolumab Plus Ipilimumab Showed Promise Among Patients With Locally Advanced Mismatch-Repair Deficient Colon Cancer
07/18/2024
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.
According to results from the...
07/18/2024
Oncology
News
Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer
07/11/2024
Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...
Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...
Final analysis results from the...
07/11/2024
Oncology
News
FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer
06/21/2024
Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.
Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.
Based on results from the...
06/21/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer
04/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.
Results from the phase 3 OPTICAL...
04/09/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
FDA Grants Approval to Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer
11/10/2023
On November 8, 2023, the FDA approved fruquintinib for the treatment of patients with metastatic colorectal cancer who had previously been treated with multiple chemotherapies, an anti-VEGF therapy, and, if necessary, an anti-EGFR therapy.
On November 8, 2023, the FDA approved fruquintinib for the treatment of patients with metastatic colorectal cancer who had previously been treated with multiple chemotherapies, an anti-VEGF therapy, and, if necessary, an anti-EGFR therapy.
On November 8, 2023, the FDA...
11/10/2023
Oncology
News
Effect of HER2 Overexpression or Amplification on Resistance to Anti-EGFR Treatment Among Patients with RAS Wild-Type Metastatic Colorectal Cancer
08/10/2023
According to a systemic review and meta-analysis, patients with HER2-positive, RAS wild-type metastatic colorectal cancer who were treated with anti-EGFR therapies were more likely to have worse progression-free survival and response than...
According to a systemic review and meta-analysis, patients with HER2-positive, RAS wild-type metastatic colorectal cancer who were treated with anti-EGFR therapies were more likely to have worse progression-free survival and response than...
According to a systemic review...
08/10/2023
Oncology
News
Second-Line Avelumab Improved PFS and Disease Control Among Patients With dMMR/MSI Metastatic Colorectal Cancer
08/10/2023
According to a phase 2 trial, avelumab had better efficacy and tolerability among patients with deficient mismatch repair and/or microsatellite instability metastatic colorectal cancer compared with standard-of-care chemotherapy.
According to a phase 2 trial, avelumab had better efficacy and tolerability among patients with deficient mismatch repair and/or microsatellite instability metastatic colorectal cancer compared with standard-of-care chemotherapy.
According to a phase 2 trial,...
08/10/2023
Oncology
News
FDA Approval of Trifluridine and Tipiracil With Bevacizumab for Patients With Previously Treated Metastatic Colorectal Cancer
08/02/2023
On August 2, 2023, the FDA granted approval to trifluridine and tipiracil plus bevacizumab for the treatment of patients with previously treated metastatic colorectal cancer.
On August 2, 2023, the FDA granted approval to trifluridine and tipiracil plus bevacizumab for the treatment of patients with previously treated metastatic colorectal cancer.
On August 2, 2023, the FDA...
08/02/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement